WHO Raises Alert Over Critical Scarcity of Obesity Medications

Less than 10% of patients that would benefit from obesity jabs like Wegovy are able to get them, caution the WHO as it issues its inaugural advice on the medications.

Considering more than one billion individuals worldwide now obese, it is calling for increased and just access to these injectable treatments.

Based on forecasts, over two billion are projected to be obese by 2030 if no action is taken.

"The latest guidance recognises that excess weight is a lifelong illness that can be managed with thorough and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and supply-chain constraints are major barriers to broad access to the treatments that can aid individuals in losing significant weight, notes the body.

Skinny Jab Supply Crisis

Despite the present most optimistic scenario, the manufacturing of GLP-1 therapies might only reach around 100 million people – less than 10% of those who need them, per the health organization.

The recommendation encourages governments and firms to widen availability, by approaches such as licensing agreements.

The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several nations in 2026.

How Obesity Drugs Function

The injections mimick a natural hormone to delay gastric emptying, suppress the appetite and boost satiety so users reduce food intake.

Patients commonly start to lose weight after several weeks of beginning the weekly injections.

Evidence indicates patients may put most of the weight back on a year later of halting the treatment, because their usual food cravings return.

To be above a healthy weight raises your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some cancers.

Excess weight impacts people in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.